All half-lives are wrong, but some half-lives are useful

Clinical Pharmacokinetics

Volumn 40, Issue 4, 2001, Pages 237-244

  Wright, James G ^a   Boddy, Alan V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INHIBITION; KIDNEY DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS;

EID: 0035016610     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140040-00001     Document Type: Review

References (33)

1. 1. Greenblatt DJ. Elimination half-life of drugs: value and limitations. Annu Rev Med 1985; 36: 421-7
2. 2. Jacobs JR, Shafer SL, Larsen JL, et al. Two equally valid interpretations of the linear multicompartmenl mammillary pharmacokinetic model. J Pharm Sci 1990; 79: 331-3
3. 3. Houston JB. Drug metabolite kinetics. Pharmacol Ther 1981; 15: 521-52
4. 4. Ronfeld RA, Benet LZ. Interpretation of plasma concentration-time curves after oral dosing. J Pharm Sci 1977; 66: 178-86
5. 5. Lind MJ, Margison M, Cerny T, et al. The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol 1990; 30: 140-3
6. 6. Sheiner LB, Wakefield J. Population modelling in drug development. Stat Methods Med Res 1999; 8: 183-93
7. 7. Rescigno A. Terminal half-life. J Pharmacokinet Biopharm 1993; 21: 125-9
8. 8. Chabner BA, Stoller RG, Hande KR. Methotrexate disposition in humans: case studies in ovarian cancer and following high dose infusion. Drug Metab Rev 1978; 8: 107-17
9. 9. Dokoumetzidis A, Iliadis A, Macheras P. An alternative method for the estimation of the terminal slope when a few data points are available. J Pharm Sci 1999; 88: 557-60
10. 10. Bryan M, Zimmerman JJ, Berry WJ. The use of half-lives and associated confidence intervals in biological research Vet Res Commun 1990; 14: 235-40
11. 11. Lacey LF, Keene ON, Pritchard JF, et al. Common non-compartmental pharmacokinetic parameters: are they normally or log-normally distributed? J Biopharm Stat 1997; 7: 171-8
12. 12. Julious SA, Debarnot CAM. Why are pharmacokinetic data summarized by arithmetic means? J Biopharm Stat 2000; 10: 55-71
13. 13. Lam FC, Hung CT, Perrier DG. Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985; 74: 229-31
14. 14. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982; 18: 143-66
15. 15. Warwick NR, Graham GG, Torda TA. Pharmacokinetic analysis of the effect of vecuronium in surgical patients: pharmacokinetic and pharmacodynamic modeling without plasma concentrations. Anesthesiology 1998; 88: 874-84
16. 16. Levy G. Kinetics of pharmacological activity of succinylcholine in man. J Pharm Sci 1967; 56 (12): 1687-8
17. 17. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995; 35 (3): 209-19
18. 18. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56
19. 19. Weiss M, Sziegoleit W, Fahr A, et al. Rapid achievement of a serum concentration plateau of digoxin through controlled infusion. Eur J Clin Pharmacol 1983; 25: 455-7
20. 20. Shafer SL, Stanski DR. Improving the clinical utility of anesthetic drug pharmacokinetics. Anesthesiology 1992; 76: 327-30
21. 21. Gamelin E, Allain P, Maillart P, et al. Long-term pharmacokinetic behaviour of platinum after cisplatin administration. Cancer Chemother Pharmacol 1995; 37: 97-102
22. 22. Schierl R, Rohrer B, Hohnloser J. Long-term platinum excretion in patients treated with cisplatin. Cancer Chemother Pharmacol 1995; 36: 75-8
23. 23. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-96
24. 24. Benet LZ, Pharmacokinetic parameters: which are necessary to define a drug substance? Eur J Respir Dis 1984; Suppl. 134: 45-61
25. 25. Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics and rational opioid selection. Anesthesiology 1991; 74: 58-63
26. 26. Hughes MA, Glass PSA, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992; 76: 334-41
27. 27. Bailey JM. Technique for quantifying the duration of intravenous anesthetic effect. Anesthesiology 1995; 83: 1095-103
28. 28. Kapila A, Glass PSA, Jacobs JR, et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology 1995; 83: 968-75
29. 29. Minto C, Schnider T, Expanding clinical applications of population pharmacodynamic modelling. Br J Clin Pharmacol 1998; 46: 321-33
30. 30. Holford NH, Kimko HC, Monteleone JP, et al. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000; 40; 209-34
31. 31. Schnider TW, Shafer SL. Evolving clinically useful predictors of recovery from intravenous anesthetics. Anesthesiology 1995; 83: 902-5
32. 32. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22: 447-67
33. 33. Box GEP. Robustness in the strategy of scientific model building. In: Launer RL, Wilkinson GN, editors. Robustness in statistics. New York: Academic Press, 1979